Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angelo Antonini

Showing results (21-30 of 495) with videos related to

Pageof 50
Sort By:
Nature Reviews. Neurology|October 4, 2018
Apomorphine infusion in advanced Parkinson diseaseAngelo Antonini, Peter Jenner
Expert Opinion on Drug Metabolism & Toxicology|September 7, 2011
Pharmacokinetic evaluation of pramipexoleAngelo Antonini, Daniela Calandrella
Expert Review of Neurotherapeutics|June 6, 2009
Apomorphine and levodopa infusion therapies for advanced Parkinson's disease: selection criteria and patient managementAngelo Antonini, Eduardo Tolosa
Sleep Medicine|March 23, 2004
PET and SPECT functional imaging in Parkinson's diseaseAngelo Antonini, Roberta DeNotaris
Expert Review of Neurotherapeutics|January 17, 2014
Novel levodopa formulations in the treatment of Parkinson's diseaseManuela Pilleri, Angelo Antonini
Nature Reviews. Neurology|July 9, 2014
Parkinson disease: Can dopamine transporter imaging define early PD?Angelo Antonini, Roberta Biundo
Expert Opinion on Drug Safety|December 9, 2014
Therapeutic strategies to prevent and manage dyskinesias in Parkinson's diseaseManuela Pilleri, Angelo Antonini
The Lancet. Neurology|July 11, 2014
Adenosine A2A receptor antagonists in Parkinson's disease: still in the runningAngelo Antonini, Werner Poewe
Movement Disorders Clinical Practice|November 15, 2025
Letter to the Editor on "Cognitive and Psychiatric Adverse Effects of Foslevodopa/Foscarbidopa in Patients with Parkinson's Disease"Bruno Bergmans, Angelo Antonini
Journal of Neural Transmission (Vienna, Austria : 1996)|July 15, 2018
Apomorphine and levodopa infusion for motor fluctuations and dyskinesia in advanced Parkinson diseaseAngelo Antonini, Bianca Nitu
Pageof 50

Showing results (21-30 of 495) with videos related to

Sort By:
Pageof 50
Nature Reviews. Neurology|October 4, 2018
Apomorphine infusion in advanced Parkinson diseaseAngelo Antonini, Peter Jenner
Expert Opinion on Drug Metabolism & Toxicology|September 7, 2011
Pharmacokinetic evaluation of pramipexoleAngelo Antonini, Daniela Calandrella
Expert Review of Neurotherapeutics|June 6, 2009
Apomorphine and levodopa infusion therapies for advanced Parkinson's disease: selection criteria and patient managementAngelo Antonini, Eduardo Tolosa
Sleep Medicine|March 23, 2004
PET and SPECT functional imaging in Parkinson's diseaseAngelo Antonini, Roberta DeNotaris
Expert Review of Neurotherapeutics|January 17, 2014
Novel levodopa formulations in the treatment of Parkinson's diseaseManuela Pilleri, Angelo Antonini
Nature Reviews. Neurology|July 9, 2014
Parkinson disease: Can dopamine transporter imaging define early PD?Angelo Antonini, Roberta Biundo
Expert Opinion on Drug Safety|December 9, 2014
Therapeutic strategies to prevent and manage dyskinesias in Parkinson's diseaseManuela Pilleri, Angelo Antonini
The Lancet. Neurology|July 11, 2014
Adenosine A2A receptor antagonists in Parkinson's disease: still in the runningAngelo Antonini, Werner Poewe
Movement Disorders Clinical Practice|November 15, 2025
Letter to the Editor on "Cognitive and Psychiatric Adverse Effects of Foslevodopa/Foscarbidopa in Patients with Parkinson's Disease"Bruno Bergmans, Angelo Antonini
Journal of Neural Transmission (Vienna, Austria : 1996)|July 15, 2018
Apomorphine and levodopa infusion for motor fluctuations and dyskinesia in advanced Parkinson diseaseAngelo Antonini, Bianca Nitu
Pageof 50